Tag
China launched its first multi-centre clinical trial of a domestically developed 128-channel fully implantable invasive brain-computer interface for quadriplegic spinal cord injury patients, enrolling 32 patients across 11 medical institutions.
Science Corporation CEO Max Hodak announced at TechCrunch Disrupt that the company has implanted its vision-restoring PRIMA chip into its first Stargardt disease patient, with the patient already able to read letters during rehabilitation. The company plans larger field-of-view next-generation implants within a year, aiming to approach native visual acuity over five years.
Rubedo Life Sciences 报告其靶向细胞衰老（senescence）的外用抗衰老乳膏在小型临床试验中让受试者皮肤生物年龄平均降低约两年，并计划扩展至银屑病、脱发及口服制剂开发。
PopVax has dosed the first participants in a Phase 1 trial of PVX-001, an open-source broadly protective COVID-19 vaccine built on its own computational protein design, mRNA-VLP, and fridge-stable LNP platform, with the design to be open-sourced after the trial concludes.
A Phase 1 clinical trial (PRiSM) has begun enrolling participants for a divalent siRNA drug candidate designed to lower prion protein levels and slow prion disease progression, developed by Broad Institute and UMass Chan Medical School scientists.
A Phase 1 trial reports what may be the first successful rejuvenation of human eye cells, using three Yamanaka factors delivered as proteins to reprogram damaged retinal ganglion cells in glaucoma patients, based on David Sinclair's epigenetic reprogramming theory.
Google's AMIE study published in The Lancet — the first prospective study of patient-facing conversational diagnostics in a real clinic setting. Testing with urgent care patients showed clinicians found AMIE's summaries helpful in 75% of cases, with 90% match on differential diagnoses.
A next-generation obesity drug, Retatrutide, shows up to 25% weight loss in clinical trials, building on GLP-1 based treatments by combining GLP-1, GIP, and glucagon hormones.
A blind patient with Stargardt disease regained the ability to read a letter after receiving the PRIMA implant in a clinical trial, showing promise for treating this form of blindness.
An experimental AI-created drug, Rentosertib, unexpectedly reduced patients' biological age indicators by about 6 years during trials for idiopathic pulmonary fibrosis.
Moderna and Merck announced positive Phase 3 results for their personalized cancer vaccine, which reduced melanoma recurrence, causing Moderna stock to surge by over 110%.
Moderna and Merck announced positive Phase 3 results for intismeran autogene, an mRNA-based individualized neoantigen therapy, in adjuvant treatment for melanoma.
An experimental mRNA-based cancer vaccine has successfully prevented melanoma from returning in a late-stage study, marking the first validation of decades of custom-treatment research.
A controversial Alzheimer's surgery is claimed to reverse symptoms, indicating a potential breakthrough in medical treatment for the disease.
Eric Topol highlights a BMJ study showing tirzepatide (Zepbound) reduces cardiovascular events, infections by 36%, and all-cause mortality by 45% compared to sitagliptin in diabetic patients with prior atherosclerotic cardiovascular disease.
Early clinical trial results suggest psilocybin, the active ingredient in magic mushrooms, could kick-start recovery in anorexia patients, offering a potential new treatment for a disorder with high mortality and limited effective therapies.
Neuralink is exploring how clinical trial participants can control a powered wheelchair using their mind, detailing the process in a thread.
A joint investigation by Science and Retraction Watch has revealed an unreported death case in China involving gene editing therapy: A 6-year-old girl died after receiving a base editing therapy that was not approved by the National Medical Products Administration, raising ethical and regulatory concerns.
This paper presents RaDaR, a 32B open-source reasoning LLM trained on public and synthetic rare disease cases, which outperforms larger models like DeepSeek-R1 in diagnosis benchmarks and improves physician accuracy by 21.44 percentage points in a randomized trial.
A biotech company has dosed its first volunteer in a clinical trial for an experimental glaucoma treatment that uses cellular reprogramming to reverse age-related damage, part of a broader trend toward rejuvenation therapies.